PPARG and type 2 diabetes mellitus: Importantly, activation of PPARγ via pioglitazone (PIO), a drug used to treat type 2 diabetes, restores lipid synthesis and IFN-γ production in those intratumoral iNKT cells, and significantly enhances anti-tumor efficacy of iNKT cell-based immunotherapy.